Phase II breast cancer chemoprevention trial of the third generation selective estrogen receptor modulator arzoxifene.

@article{Fabian2006PhaseIB,
  title={Phase II breast cancer chemoprevention trial of the third generation selective estrogen receptor modulator arzoxifene.},
  author={Carol J. Fabian and Bruce F Kimler and James R. Anderson and Carolyn Chamberlain and Matthew S. Mayo and Carola M. Zalles and Joyce O'Shaughnessy and Henry T. Lynch and Karen Anne Johnson and Doris Browne},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={1001}
}
1001 Background: Arzoxifene (ARZ) is a third generation SERM with efficacy in metastatic breast cancer but lacking uterine agonist activity. METHODS We conducted a randomized, double-blind, placebo-controlled Phase II prevention trial in 199 high risk women assessing the effects of ARZ 20 mg/day on several risk biomarkers. Biomarkers, including cytomorphology of breast epithelial cells obtained by random periareolar FNA (RPFNA) were assessed at baseline and following 6 months of placebo or… CONTINUE READING